Janice S Withycombe, Aimee Carlson, Carly Coleman, Sharon L Leslie, Micah Skeens, Hanna Tseitlin, Elizabeth A Duffy
{"title":"Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children's Oncology Group","authors":"Janice S Withycombe, Aimee Carlson, Carly Coleman, Sharon L Leslie, Micah Skeens, Hanna Tseitlin, Elizabeth A Duffy","doi":"10.1177/1043454220966590","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immunotherapy is a new and promising approach to treating pediatric cancers. These types of therapies have unique mechanisms of action for identifying and fighting cancer, as compared with traditional chemotherapy, and therefore are associated with different therapy-related adverse events (AEs). The purpose of this systematic review was to review available evidence to: (a) identify commonly reported AEs associated with immunotherapy agents frequently used in pediatric oncology and (b) generate recommendations for nursing practice.</p><p><strong>Method: </strong>A clinical question was developed and used to guide the systematic literature review. Five immunotherapy agents (dinutuximab, blinatumomab, rituximab, inotuzumab ozogamicin, brentuximab vedotin) were selected for inclusion secondary to their high relevance to pediatric oncology. A literature search was conducted to locate articles published between January 1, 2003 and October 31, 2018.</p><p><strong>Results: </strong>Seventeen articles met eligibility criteria for inclusion and were evaluated using the Grading of Recommendations Assessment, Development, and Evaluation criteria. The most commonly reported AEs for the selected immunotherapy agents were identified and summarized. Strong recommendations are made for nurses to become familiar with the unique AE profiles associated with individual immunotherapy agents. Agent-specific recommendations for nursing practice regarding AEs associated with dinutuximab and rituximab were generated.</p><p><strong>Conclusions: </strong>Immunotherapy is rapidly emerging as an effective therapy for pediatric cancers. Nurses need to be aware of the breadth of agent-specific, immunotherapy-related AEs to appropriately monitor and manage patients receiving these therapies. Additional work is needed to confidently profile immunotherapy-related AEs in pediatric oncology and to develop agent-specific educational materials for patients/families.</p>","PeriodicalId":50093,"journal":{"name":"Journal of Pediatric Oncology Nursing","volume":"38 1","pages":"16-25"},"PeriodicalIF":1.9000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822201/pdf/10.1177_1043454220966590.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Oncology Nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1043454220966590","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/10/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Immunotherapy is a new and promising approach to treating pediatric cancers. These types of therapies have unique mechanisms of action for identifying and fighting cancer, as compared with traditional chemotherapy, and therefore are associated with different therapy-related adverse events (AEs). The purpose of this systematic review was to review available evidence to: (a) identify commonly reported AEs associated with immunotherapy agents frequently used in pediatric oncology and (b) generate recommendations for nursing practice.
Method: A clinical question was developed and used to guide the systematic literature review. Five immunotherapy agents (dinutuximab, blinatumomab, rituximab, inotuzumab ozogamicin, brentuximab vedotin) were selected for inclusion secondary to their high relevance to pediatric oncology. A literature search was conducted to locate articles published between January 1, 2003 and October 31, 2018.
Results: Seventeen articles met eligibility criteria for inclusion and were evaluated using the Grading of Recommendations Assessment, Development, and Evaluation criteria. The most commonly reported AEs for the selected immunotherapy agents were identified and summarized. Strong recommendations are made for nurses to become familiar with the unique AE profiles associated with individual immunotherapy agents. Agent-specific recommendations for nursing practice regarding AEs associated with dinutuximab and rituximab were generated.
Conclusions: Immunotherapy is rapidly emerging as an effective therapy for pediatric cancers. Nurses need to be aware of the breadth of agent-specific, immunotherapy-related AEs to appropriately monitor and manage patients receiving these therapies. Additional work is needed to confidently profile immunotherapy-related AEs in pediatric oncology and to develop agent-specific educational materials for patients/families.
期刊介绍：
SPECIAL PATIENTS NEED SPECIAL NURSES
Caring for children with cancer is one of the most technically and emotionally difficult areas in nursing. Not only are you dealing with children and adolescents who hurt, you must reassure and educate families, balance a multitude of other health care professionals, and keep up with ever-changing nursing practice and care. To help special nurses stay aware of the newest effective nursing practices, innovative therapeutic approaches, significant information trends, and most practical research in hematology and pediatric oncology nursing, you need the Journal of Pediatric Oncology Nursing.
The journal offers pediatric hematology, oncology, and immunology nurses in clinical practice and research, pediatric social workers, epidemiologists, clinical psychologists, child life specialists and nursing educators the latest peer-reviewed original research and definitive reviews on the whole spectrum of nursing care of childhood cancers, including leukemias, solid tumors and lymphomas, and hematologic disorders. JOPON covers the entire disease process--diagnosis, treatment, recovery, and survival, as well as end-of-life care.
Six times a year, the Journal of Pediatric Oncology Nursing introduces new and useful nursing care practice and research from around the world that saves you time and effort. Just some of the spirited topics covered include:
Cancer survivorship including later-life effects of childhood cancer, including fertility, cardiac insufficiency, and pulmonary fibrosis
Combination therapies
Hematologic and immunologic topics
Holistic, family-centered supportive care
Improvement of quality of life for children and adolescents with cancer
Management of side effects from surgery, chemotherapy, and radiation
Management of specific symptoms/diseases/co-infections
Medication tolerance differences in children and adolescents
Pain control
Palliative and end of life care issues
Pharmacologic agents for pediatrics/clinical trial results
Psychological support for the patient, siblings, and families
The dynamic articles cover a wide range of specific nursing concerns, including:
Advanced practice issues
Clinical issues
Clinical proficiency
Conducting qualitative and quantitative research
Developing a core curriculum for pediatric hematology/oncology nursing
Encouraging active patient participation
Ethical issues
Evaluating outcomes
Professional development
Stress management and handling your own emotions
Other important features include Guest Editorials from experts in the discipline, Point/Counterpoint debates, Roadmaps (personal insights into the nursing experience), and Proceedings and Abstracts from the annual Association for Pediatric Hematology/Oncology Nurses (APHON) conference.
Your special patients need special nurses--stay special by subscribing to the Journal of Pediatric Oncology Nursing today!
This journal is a member of the Committee on Publication Ethics (COPE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
